Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;20(2):337-340.
doi: 10.1007/s11739-025-03862-1. Epub 2025 Jan 27.

SGLT-2 inhibitors and diabetic ketoacidosis

Francesco Agozzino  1 , Teresa De Falco  2 , Antonio Villa  2
Affiliations

SGLT-2 inhibitors and diabetic ketoacidosis

Francesco Agozzino et al. Intern Emerg Med. 2025 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: None to declare. Human and animal rights statement and Informed consent: As a Commentary, we did not collect any original data, authorization by local ethic commission was not necessary, informed consent and other indications from the Declaration of Helsinki were not applicable. Data availability: As a Commentary, we did not collect any original data which could be shared.

References

    1. American Diabetes Association Professional Practice Committee (2024) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes 2024. Diabetes Care 47(Suppl 1):S158–S178. https://doi.org/10.2337/dc24-S009 - DOI
    1. Davies MJ, Aroda VR, Collins BS et al (2022) Management of Hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45:2753–2786. https://doi.org/10.2337/dci22-0034 - DOI - PubMed - PMC
    1. Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39. https://doi.org/10.1016/S0140-6736(18)32590-X - DOI - PubMed
    1. Neuen BL, Young T, Heerspink HJL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta analysis. Lancet Diabetes Endocrinol 7:845–854. https://doi.org/10.1016/S22138587(19)30256-6 - DOI - PubMed
    1. Patel SM, Kang YM, Im K et al (2024) Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta analysis. Circulation 149:1789–1801. https://doi.org/10.1161/CIRCULATIONAHA.124.069568 - DOI - PubMed - PMC

LinkOut - more resources